Metformin and inflammation: Its potential beyond glucose-lowering effect

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscle. Metformin also has been shown to reduce cardiovascular events in randomized controlled trials; however, the underlying mechanism remains to be established. Recent preclinical and clinical studies have suggested that metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, but also has a direct anti-inflammatory action. Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor κB (NFκB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. This review summarizes the basic and clinical evidence of the anti-inflammatory action of metformin and discusses its clinical implication.

Original languageEnglish
Pages (from-to)196-205
Number of pages10
JournalEndocrine, Metabolic and Immune Disorders - Drug Targets
Volume15
Issue number3
Publication statusPublished - 2015 Sep 1

Fingerprint

Metformin
Inflammation
Glucose
Hyperglycemia
Anti-Inflammatory Agents
AMP-Activated Protein Kinases
Dyslipidemias
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Insulin Resistance
Randomized Controlled Trials
Muscles
Liver

Keywords

  • AMPK
  • Anti-inflammatory effect
  • Biguanide
  • NFκB
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy

Cite this

Metformin and inflammation : Its potential beyond glucose-lowering effect. / Saisho, Yoshifumi.

In: Endocrine, Metabolic and Immune Disorders - Drug Targets, Vol. 15, No. 3, 01.09.2015, p. 196-205.

Research output: Contribution to journalArticle

@article{e4b2dd72bc7e462a8654fc272b0d6f7e,
title = "Metformin and inflammation: Its potential beyond glucose-lowering effect",
abstract = "Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscle. Metformin also has been shown to reduce cardiovascular events in randomized controlled trials; however, the underlying mechanism remains to be established. Recent preclinical and clinical studies have suggested that metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, but also has a direct anti-inflammatory action. Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor κB (NFκB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. This review summarizes the basic and clinical evidence of the anti-inflammatory action of metformin and discusses its clinical implication.",
keywords = "AMPK, Anti-inflammatory effect, Biguanide, NFκB, Type 2 diabetes",
author = "Yoshifumi Saisho",
year = "2015",
month = "9",
day = "1",
language = "English",
volume = "15",
pages = "196--205",
journal = "Endocrine, metabolic & immune disorders drug targets",
issn = "1871-5303",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Metformin and inflammation

T2 - Its potential beyond glucose-lowering effect

AU - Saisho, Yoshifumi

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscle. Metformin also has been shown to reduce cardiovascular events in randomized controlled trials; however, the underlying mechanism remains to be established. Recent preclinical and clinical studies have suggested that metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, but also has a direct anti-inflammatory action. Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor κB (NFκB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. This review summarizes the basic and clinical evidence of the anti-inflammatory action of metformin and discusses its clinical implication.

AB - Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscle. Metformin also has been shown to reduce cardiovascular events in randomized controlled trials; however, the underlying mechanism remains to be established. Recent preclinical and clinical studies have suggested that metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, but also has a direct anti-inflammatory action. Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor κB (NFκB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. This review summarizes the basic and clinical evidence of the anti-inflammatory action of metformin and discusses its clinical implication.

KW - AMPK

KW - Anti-inflammatory effect

KW - Biguanide

KW - NFκB

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84942115958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942115958&partnerID=8YFLogxK

M3 - Article

C2 - 25772174

AN - SCOPUS:84942115958

VL - 15

SP - 196

EP - 205

JO - Endocrine, metabolic & immune disorders drug targets

JF - Endocrine, metabolic & immune disorders drug targets

SN - 1871-5303

IS - 3

ER -